RecruitingNot ApplicableNCT06522256

Identification of Molecular Signatures of High-risk Oncogenic HPV and Study of Their Associations With the Presence of High-grade Lesions and/or Anal Cancer 10 Years After Inclusion in the ANRS IPERGAY Trial

Sponsor

ANRS, Emerging Infectious Diseases

Enrollment

100 participants

Start Date

Mar 20, 2025

Study Type

INTERVENTIONAL

Conditions

Anal Cancer HPV Infection

Summary

HPVsign is a cross-sectional, non-comparative, multicenter study involving all participants included in the HPV substudy of the ANRS IPERGAY trial. The study proposes to evaluate the cumulative incidence of high-grade lesions and/or anal cancers using high-resolution anoscopy (HRA) during the HPVsign study and/or diagnosed since the end of participation in the ANRS IPERGAY trial.

Eligibility

Min Age: 18 Years

Inclusion Criteria3

Participant in the ANRS IPERGAY clinical trial who was included in the initial HPV sub-study;
Informed and written signed consent
Participant with regular health insurance

Exclusion Criteria3

Participant under guardianship or curatorship
Participant with free State medical assistance
Participant who disagrees with the use of data collected as part of their participation in the ANRS IPERGAY trial.

Interventions

PROCEDUREHigh-resolution anoscopy

The study includes 2 visits: * a medical consultation for inclusion * a proctology consultation including the performance of an AHR associated or not with biopsy sampling